Compare CALM & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALM | CPRX |
|---|---|---|
| Founded | 1957 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.4B |
| IPO Year | 1996 | 2006 |
| Metric | CALM | CPRX |
|---|---|---|
| Price | $75.28 | $31.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $92.00 | $35.00 |
| AVG Volume (30 Days) | 659.0K | ★ 2.9M |
| Earning Date | 04-01-2026 | 05-11-2026 |
| Dividend Yield | ★ 11.13% | N/A |
| EPS Growth | ★ 338.49 | 28.24 |
| EPS | ★ 7.34 | 0.50 |
| Revenue | ★ $1,351,609,000.00 | $119,072,803.00 |
| Revenue This Year | N/A | $9.20 |
| Revenue Next Year | N/A | $10.51 |
| P/E Ratio | ★ $10.41 | $62.58 |
| Revenue Growth | N/A | ★ 16.39 |
| 52 Week Low | $71.92 | $19.05 |
| 52 Week High | $126.40 | $32.56 |
| Indicator | CALM | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.94 | 72.86 |
| Support Level | $72.83 | $31.00 |
| Resistance Level | $79.75 | $31.33 |
| Average True Range (ATR) | 2.34 | 0.08 |
| MACD | -0.09 | -0.19 |
| Stochastic Oscillator | 27.23 | 81.94 |
Cal-Maine Foods Inc produces and sells shell eggs. Its main market is the United States. The company's product portfolio contains nutritionally enhanced, cage-free, organic, and brown eggs. Cal-Maine Foods markets the shell eggs to a diverse group of customers, including grocery-store chains, club stores, and food service distributors. The company's brands are Egg-Land's, Land O' Lakes, Farmhouse, and 4-Grain. The Company has one reportable operating segment, which is the production, grading, packaging, marketing and distribution of shell eggs.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.